| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced Analgesic Drug Delivery and Nanobiotechnology
|
Stoicea, Nicoleta
|
|
2017
|
77 |
10 |
p. 1069-1076
|
artikel
|
| 2 |
Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects
|
Flamant, Mathurin
|
|
2017
|
77 |
10 |
p. 1057-1068
|
artikel
|
| 3 |
Authors’ Reply to Schoenfeld: “Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors”
|
Michiels, Stefan
|
|
2017
|
77 |
10 |
p. 1139-1140
|
artikel
|
| 4 |
Brigatinib: First Global Approval
|
Markham, Anthony
|
|
2017
|
77 |
10 |
p. 1131-1135
|
artikel
|
| 5 |
Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors
|
Schoenfeld, David A.
|
|
2017
|
77 |
10 |
p. 1137-1138
|
artikel
|
| 6 |
Dupilumab: First Global Approval
|
Shirley, Matt
|
|
2017
|
77 |
10 |
p. 1115-1121
|
artikel
|
| 7 |
Erratum to: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
|
Geloneze, Bruno
|
|
2017
|
77 |
10 |
p. 1141
|
artikel
|
| 8 |
Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives
|
Farina, Matthew S.
|
|
2017
|
77 |
10 |
p. 1077-1089
|
artikel
|
| 9 |
Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor
|
Hubbard, Joleen M.
|
|
2017
|
77 |
10 |
p. 1091-1103
|
artikel
|
| 10 |
Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use
|
Bagaglio, Sabrina
|
|
2017
|
77 |
10 |
p. 1043-1055
|
artikel
|
| 11 |
Ustekinumab: A Review in Moderate to Severe Crohn’s Disease
|
Lamb, Yvette N.
|
|
2017
|
77 |
10 |
p. 1105-1114
|
artikel
|
| 12 |
Valbenazine: First Global Approval
|
Kim, Esther S.
|
|
2017
|
77 |
10 |
p. 1123-1129
|
artikel
|
Tijdschrift beschrijving